

## EQA round: GP1/23 - Detection of Monoclonal Components

Deadline: 3.3.2023

Setup: groups - manufacturer of kit

AV = assigned value

N<sub>tot</sub> = total number of the resultsN<sub>eva</sub> = number of the results assessedN<sub>rel</sub> = relative number of the resultsN<sub>suc</sub> = number of successful results

&gt;&gt;&gt; ... expected result

S<sub>rel</sub> = relative success

&gt; ... acceptable result

± ... result not assessed

Test Sample Group	Frequency of the results				Success		
	AV	N <sub>tot</sub>	N <sub>rel</sub> [%]	Result	N <sub>eva</sub>	N <sub>suc</sub>	S <sub>rel</sub> [%]
<b>(246) Gammopathies (typisation)</b>		93			93	80	86
<b>Sample A</b>		93			93	87	94
(12) Beckman Coulter	CVP >>>	1	1,1	IgM-kappa			
(34) Sebia		1	1,1	IgA-kappa			
		1	1,1	IgG-kappa			
	CVP >>>	59	63	IgM-kappa			
		2	2,2	Monoclonal immunoglobulin not present			
(100) Helena	CVP >>>	1	1,1	IgM-kappa			
(213) Interlab Srl	CVP >>>	26	28	IgM-kappa			
		2	2,2	Monoclonal immunoglobulin not present			
<b>Sample B</b>		93			93	86	92
(12) Beckman Coulter	CVP >>>	1	1,1	IgM-kappa			
(34) Sebia	CVP >>>	57	61	IgM-kappa			
		1	1,1	IgM-kappa; IgG-kappa			
		1	1,1	IgM-kappa; kappa-free			
		1	1,1	IgM-kappa; IgA-lambda			
		1	1,1	IgM-kappa; IgM-lambda			
		2	2,2	IgM-kappa; lambda-free			
(100) Helena	CVP >>>	1	1,1	IgM-kappa			
(213) Interlab Srl	CVP >>>	27	29	IgM-kappa			
		1	1,1	IgM-kappa; IgM-lambda			